TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma

Table 3

The relationship between TAZ and clinicopathological characteristics.

Characteristics	TAZ protein levels		𝑃	TAZ mRNA levels	𝑃
	low IHC (0∼1+)	High IHC (2+∼3+)
Age			0.294		0.374
<60	15 (24.2%)	47 (75.8%)		4.45±4.84
≥60	27 (32.1%)	57 (67.9%)		3.92±4.93
Sex			0.376		0.696
Female	8 (22.9%)	27 (77.1%)		4.71±6.44
Male	34 (30.6%)	77 (69.4%)		3.99±4.32
Histology			0.001		0.003
Adenocarcinoma	33 (39.8%)	50 (60.2%)		3.15±3.25
SRCC	9 (14.3%)	54 (85.7%)		6.71±7.02
Tumor site			0.159		0.069
Distal stomach	13 (26.5%)	36 (73.5%)		5.43±6.02
Proximal stomach	17 (41.5%)	24 (58.5%)		2.2±2.31
Whole stomach	11 (22.9%)	37 (77.1%)		4.37±4.82
Unknown	1 (12.5%)	7 (87.5%)		2.94±1.51
Lymph node			0.232		0.899
N0-1	8 (40%)	12 (60%)		4.8±6.99
N2-3	34 (27%)	92 (73%)		4.04±4.45
Stage			0.785		0.492
II	1 (16.7%)	5 (83.3%)		3.60±2.30
III	40 (29.4%)	96 (70.6%)		4.24±5.05
IV	1 (25%)	3 (75%)		2.80±2.59
Histological grade			0.004		0.375
G2	16 (48.5%)	17 (51.5%)		4.05±5.86
G3	26 (23%)	87 (77%)		4.19±4.54